Siemens Healthineers stock plunges to 52-week low amid market and reform pressures
Siemens Healthineers has seen its stock price tumble to a 52-week low, hitting €35.66 in late March 2026. The decline extends its year-to-date losses to nearly 20%, sharply underperforming rivals like GE HealthCare and Medtronic. Analysts now watch the €42.00 level as a key resistance point amid growing market concerns. The company's shares have struggled since the start of the year, falling between 19% and 29% by late March. This drop contrasts with gains from competitors such as GE HealthCare (+12% YTD), Medtronic (+8%), and Stryker (+15%). Challenges including weak demand in China, US tariffs, and plans for a Siemens spin-off have weighed on investor confidence.
Deutsche Bank recently downgraded Siemens Healthineers to a 'Hold' rating, reflecting cautious sentiment. Meanwhile, Barclays and RBC have kept their price targets steady at €55.00. The company's core business—selling advanced imaging and diagnostic equipment to hospitals and specialists—faces additional pressure from upcoming healthcare reforms in Germany. New proposals could require patients to see a general practitioner before accessing specialist care. Debates over statutory health insurance funding may also limit medical facilities' ability to invest in high-end equipment. These changes add to the short-term uncertainty surrounding the stock.
Siemens Healthineers now trades near its lowest point in a year, with analysts marking €42.00 as the next critical threshold. The combination of regulatory risks, market headwinds, and reform pressures continues to dampen investor outlook. The company's performance will likely depend on how these challenges unfold in the coming months.
